Lupin Seeks Partners For Biosimilars And Oncology Research
FY22 Guidance Lowered
Executive Summary
Buoyed by a $50m milestone payment for a MEK inhibitor licensed to Boehringer Ingelheim and in a bid to mitigate the burn on profits, Lupin is considering partnerships for biosimilars, specialty products and other NCEs with recently spun-off oncology assets being first in line for a deal. But FY22 earnings guidance has been lowered.
You may also be interested in...
Biosimilars Players Climb Global Rankings
Biosimilars players are gaining an increasing foothold in the off-patent industry, as demonstrated by the final part of our annual Top 50 ranking.
Glenmark Fulfills Promise To Introduce Tiotropium In Europe
India’s Glenmark had noted recently that market entry was forthcoming for a generic Boehringer Ingelheim’s Spiriva Handihaler, and has now delivered with an initial UK launch.
Lupin Gets Head Start On Brovana With US Authorized Generic
Lupin has gained a head start on other US generic rivals to Sunovion’s Brovana treatment for COPD with the launch of an authorized generic version of arformoterol tartrate inhalation solution.